scholarly journals Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (42) ◽  
pp. 69041-69050 ◽  
Author(s):  
Kai-Hua Chen ◽  
Xiao-Dong Zhu ◽  
Ling Li ◽  
Song Qu ◽  
Zhen-Qiang Liang ◽  
...  
Oncotarget ◽  
2017 ◽  
Vol 8 (44) ◽  
pp. 78096-78104 ◽  
Author(s):  
Xin-Bin Pan ◽  
Kai-Hua Chen ◽  
Shi-Ting Huang ◽  
Yan-Ming Jiang ◽  
Jia-Lin Ma ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (22) ◽  
pp. 33408-33417 ◽  
Author(s):  
Pu-Yun OuYang ◽  
Dingbo Shi ◽  
Rui Sun ◽  
Yu-Jia Zhu ◽  
Yao Xiao ◽  
...  

2016 ◽  
Vol 7 (6) ◽  
pp. 664-670 ◽  
Author(s):  
Xiao-Jing Du ◽  
Ling-Long Tang ◽  
Yan-Ping Mao ◽  
Rui Guo ◽  
Ying Sun ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6063-6063
Author(s):  
Min Kang ◽  
Shaomin Lin ◽  
Haisheng Zhu ◽  
Sihui Liao ◽  
Haixin Huang ◽  
...  

6063 Background: A prospective, randomized, and multicentric phase II study was performed to evaluate the short-term efficacy and safety of Endostar plus intensity-modulated radiotherapy (IMRT) versus concurrent chemoradiotherapy(CCRT) in locally advanced low-risk nasopharyngeal carcinoma(NPC). Methods: From September 2014 to August 2016, 120 patients with low-risk NPC at stages III-IVa from 9 centers were randomly divided into experimental group (Endostar plus radiotherapy (ERT); n = 60) and control group (CCRT; n = 60). ERT patients were given Endostar (7.5 mg/m2/day) by continuous intravenous infusion (CIV) from 5 days before radiotherapy for consecutive 10 days for 2 cycles with an interval of 14 days. Then, ERT patients received 2 cycles of 10 days of maintenance treatment with Endostar after radiotherapy. The CCRT patients were given cisplatin (100 mg/m2) on days 1, 22, and 43 for 3 cycles. Immediate and 3-month efficacy and adverse effects were evaluated between the two groups. ClinicalTrials registration number was NCT02237924. Results: All patients were eligible for toxicity and response analysis. Regarding immediate efficacy, the complete response(CR) rates were 45.0% for ERT arm and 33.3% for CCRT arm in nasopharynx (P = 0.190), and 43.3% for ERT arm and 36.7% for CCRT arm in regional nodes (P = 0.456). Three months after RT, the CR rates were 71.2% for ERT arm and 60.0% for CCRT arm in nasopharynx (P = 0.151), and 74.6% for ERT arm and 63.3% for CCRT arm in regional nodes (P = 0.172). The rate and severity of leukopenia, hemoglobin reduction and thrombocytopenia in ERT arm were significantly lower than CCRT arm (P < 0.01). The occurrence rates of Xerostomia, oral mucositis, nausea / vomiting, constipation and weight loss in ERT arm were significantly lower than those in CCRT arm (P < 0.01). Conclusions: The present study demonstrates that ERT has similar short-term efficacy on locally advanced low-risk NPC compared with CCRT, but the acute adverse effects of ERT are fewer, and the compliance and tolerability of patients are better. Clinical trial information: NCT02237924.


Sign in / Sign up

Export Citation Format

Share Document